Published: Thu, May 25, 2017
Economy | By Melissa Porter

Puma Biotechnology Inc Q4 2016 Institutional Investor Sentiment Better Than Expected

Puma Biotechnology Inc Q4 2016 Institutional Investor Sentiment Better Than Expected

Cam A S has invested 0.02% in Puma Biotechnology Inc (NASDAQ:PBYI). Virginia Retirement Et Al owns 12,100 shares. About 313,103 shares traded. Stock with the highest EPSGR rises fastest in that year as compared to its competitors in the same industry. It has by 0.00% the S&P500. The other 5 are split, though not evenly, between analysts who think you should buy its stock versus those who think you should sell it. Orbimed Advsr Ltd Llc holds 2.28 million shares. Logmein Inc now has $5.97B valuation. Ameritas Investment invested in 2,175 shares or 0.01% of the stock. About 369,258 shares traded. Canadian National Railway has $83 highest and $55 lowest target. (NASDAQ:PBYI) was up 39.15% at $52.60 on Monday, in a 52-week range of $27.64 to $73.27 and with a consensus analyst target price of $72.50. The rating was maintained by Nomura with "Neutral" on Tuesday, April 26. On Friday, August 28 the stock rating was downgraded by Vetr to "Strong-Buy". The stock has "Overweight" rating by Morgan Stanley on Tuesday, February 23. The rating was upgraded by Citigroup to "Buy" on Monday, December 14. Deutsche Bank & Trust Ag holds 296,971 shares. Exxon Mobil Corp (NYSE:XOM) was raised too. The company posted EPS of $-2.05 for the same quarter a year ago. It has a 12.93 P/E ratio.

Investors sentiment decreased to 1.32 in Q4 2016. Its down 0.17, from 1.49 in 2016Q3. It dived, as 36 investors sold PBYI shares while 21 reduced holdings. The stock grabbed 35 new institutional investments totaling 4,175,922 shares while 20 institutional investors sold out their entire positions totaling 634,153 shares. In a transaction dated January 20, 2017, the shares were put up for sale at an average price of $33.24, raking in a sum of $76,120. The firm's Chris Shibutani told investors that it is incrementally positive, at least, that the report lacked any significant new "unknown unknowns". California State Teachers Retirement Sys reported 0% of its portfolio in Puma Biotechnology Inc (NASDAQ:PBYI). The firm has "Overweight" rating by JP Morgan given on Wednesday, July 27.

Matthew Eckler, an analyst at RBC Capital Markets, said in a research note that he would be surprised if neratinib emerges completely unscathed from the panel meeting, but that the odds are tipped in its favor. Rothschild Asset Mgmt accumulated 24,176 shares or 0.01% of the stock.

04/11/2016 - Puma Biotechnology Inc had its " rating reiterated by analysts at UBS. Tourbillon Cap Ptnrs Ltd Partnership holds 448,471 shares. Northern Trust stated it has 329,526 shares or 0% of all its holdings. Sivik Health Limited Liability accumulated 30,000 shares or 0.44% of the stock.

In the transaction dated January 20, 2017, the great number of shares disposed came courtesy the; EYLER CHARLES R disposed a total of 820 shares at an average price of $33.24, amounting to approximately $27,257. About 8.98M shares traded or 755.24% up from the average. The insider now directly owns 9,680 shares worth $509,168. (NASDAQ:PBYI), with 3 analysts believing it is a strong buy. Blackrock Advsrs Llc owns 67,799 shares. Dave & Busters Entmt Inc (NASDAQ:PLAY) was raised too. Therefore 83% are positive. (PBYI) now has a value of $52.6 while the company's 52 week low is at $27.64, the shares dropped to the 52 week low on 06/27/16. A rating of 3 would signify a consensus Hold recommendation.

For the Current Quarter, the growth estimate for Puma Biotechnology, 5.9%, while for the Next Quarter the stock growth estimate is -20.8%.

Puma Biotechnology (NYSE:PBYI) last issued its quarterly earnings data on Wednesday, May 10th.

Like this: